Figure 4.
VITT plasma induces increased PLT-leukocyte (Leuk) interaction via SYK-dependent pathways. Representative FC dot plots and quantification of (A) PLT-Leuk (CD41/CD45 double positive), (B) PLT-neutrophil (Neut; CD41/CD15 double positive), and (C) PLT-monocyte (Mono; CD41/CD14 double-positive events) interaction in WB after incubation with SFLLRN (5 μM) and VITT (n = 4) or HC plasma (n = 5). Impact of SYK inhibitor pretreatment on VITT plasma–induced (D) PLT-Leuk (CD41/CD45 double positive), (E) PLT-Neut (CD41/CD15 double positive), and (F) PLT-Mono interactions (CD41/CD14 double positive) in WB. As indicated, WB was pretreated with SYK inhibitor R406 or lanraplenib (5 μM), respectively. Aggregate data in bar graph showing the distribution of the values from n = 4 individual plasma samples. Unpaired or paired t test is shown. ∗P < .05. ns, nonsignificant.

VITT plasma induces increased PLT-leukocyte (Leuk) interaction via SYK-dependent pathways. Representative FC dot plots and quantification of (A) PLT-Leuk (CD41/CD45 double positive), (B) PLT-neutrophil (Neut; CD41/CD15 double positive), and (C) PLT-monocyte (Mono; CD41/CD14 double-positive events) interaction in WB after incubation with SFLLRN (5 μM) and VITT (n = 4) or HC plasma (n = 5). Impact of SYK inhibitor pretreatment on VITT plasma–induced (D) PLT-Leuk (CD41/CD45 double positive), (E) PLT-Neut (CD41/CD15 double positive), and (F) PLT-Mono interactions (CD41/CD14 double positive) in WB. As indicated, WB was pretreated with SYK inhibitor R406 or lanraplenib (5 μM), respectively. Aggregate data in bar graph showing the distribution of the values from n = 4 individual plasma samples. Unpaired or paired t test is shown. ∗P < .05. ns, nonsignificant.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal